Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00996502 · ClinicalTrials.gov registry record · Phase 1
Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
A Phase 1 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00996502: Clinical Trial Phase 1 study, sponsored by Columbia University.
NCT00996502 is a Phase 1 study that was terminated before completion, run by Columbia University. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00996502, a Phase 1 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the safety and best dose of a regimen including bevacizumab and erlotinib in combination with docetaxel and prednisone. In addition, the investigators wish to evaluate how well these drugs might work against this disease. Bevacizumab and erlotinib are novel drugs that attack the blood vessels supplying the tumor cells and attack a receptor on the tumor cells, respectively. This study has two parts. In the first part of the study, eighteen patients will be enrolled. Patients will receive escalating doses of docetaxel in combination with standard doses of bevacizumab and erlotinib until the safest dose is determined. An additional 37 patients will enter into the second part of the study and all will receive the safest dose. In this part of the study, the effectiveness of this regimen against hormone refractory prostate cancer (HRPC) will be monitored by evaluating prostate-specific antigen (PSA) and objective response of the tumor.
Interventions
- DRUG Bevacizumab
- DRUG Docetaxel
- DRUG Prednisone
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Why NCT00996502 stopped before completion
NCT00996502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00996502 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00996502 about?
NCT00996502 is a clinical study titled "Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer". The primary objectives of this study are to evaluate the safety and best dose of a regimen including bevacizumab and erlotinib in combination with docetaxel and prednisone. In addition, the investigators wish to evaluate how well these drugs might work against this disease. Bevacizumab and erlotinib...
What is the current status of trial NCT00996502?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2006-07. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00996502?
The interventions under investigation include: Bevacizumab (DRUG), Docetaxel (DRUG), Prednisone (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00996502?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00996502's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia